FDA
-
-
-
-
-
-
-
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
-
-
-
-
-
-
-
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
-
-
-
-
-
-
-
Harrow completes acquisition of Melt Pharmaceuticals for sedation therapies
-
-
-
-
-
-
-
Harrow Health (HROW) PT Raised to $70 at B.Riley
-
-
-
-
-
-
-
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
-
-
-
-
-
-
-
H.C. Wainwright Starts Harrow Health (HROW) at Buy
-
-
-
-
-
-
-
Harrow Health (HROW) Relaunches TRIESENCE
-
326,426 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

